Physician profile
Amy L Shultz
NPI 1063462430
$19,198.64
in general payments reported to CMS, 2019-2025
31 companies · $4,290 in 2025
The $4,290 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,364 · 2020: $2,318 · 2021: $2,536 · 2022: $2,724 · 2023: $2,694 · 2024: $2,272 · 2025: $4,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,699 · Consulting Fee: $2,280 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,698.94 |
| Consulting Fee | $2,280.00 |
| Education | $277.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,136.70 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,908.37 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,670.06 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Astrazeneca Pharmaceuticals LP | $1,442.85 | 2021-2025 | Saphnelo |
| Ucb, INC. | $1,283.60 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,021.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $713.25 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $654.31 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $605.61 | 2020-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $604.94 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $566.40 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $396.64 | 2019-2025 | Actemra |
| Horizon Therapeutics Plc | $379.36 | 2020-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $315.27 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $307.13 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $288.40 | 2022-2025 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $231.31 | 2019-2022 | |
| Genzyme Corporation | $214.62 | 2019-2024 | |
| Fresenius Kabi USA, LLC | $82.08 | 2024-2025 | Idacio |
| Sandoz INC. | $74.76 | 2023-2024 | Hyrimoz |
| Radius Health, INC. | $51.94 | 2019-2025 | Tymlos |
| Pacira Therapeutics, INC. | $46.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.01 | 2023-2025 | Cyltezo, Ofev |
| Celgene Corporation | $29.08 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $25.66 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $21.52 | 2024 | Uptravi, Opsumit |
| Pacira Pharmaceuticals Incorporated | $20.12 | 2024 | Iovera, Zilretta |
| Tonix Medicines, INC. | $19.33 | 2025 | Tonmya |
| Mylan Institutional INC. | $18.34 | 2023 | Hulio |
| Antares Pharma, INC. | $15.71 | 2020 | |
| Boston Scientific Corporation | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.